Glauconix Biosciences is a specialty pharma research company that uses an innovative platform technology to reduce the cost of ophthalmic drug development.
We have validated models for Glaucoma and a recently released 3D retinal vasculature model for DR/DME that recapitulates the retinal microvasculature that incorporates human retinal pericytes cells
Glauconix’s 3D tissue system can reduce the risk of clinical trial failure; saving time, labor and development costs. Early identification and validation of effective compounds or biologics, allows partners to confidently enter clinical trials.